WINNIPEG, AB, Oct. 5, 2020 /CNW/ - Medicure Inc.
("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a
pharmaceutical company, announces that through its wholly-owned
subsidiary, Medicure International Inc., it has entered into a
License, Manufacture and Supply Agreement (the "Agreement") with
Reliance Life Sciences Private Limited ("RLS") for a cardiovascular
biosimilar (the "Product"). Medicure is responsible for the
regulatory approval process for the Product. A biosimilar is a
biological product that is highly similar to and has no clinically
meaningful differences from an approved reference product. The
Agreement grants an exclusive right to Medicure to market and sell
the Product in the United States of
America, Canada and the
European Union.
"We are very pleased with the agreement we have reached with
RLS. The Product fits well with Medicure's mission of being a
significant cardiovascular company focused on the U.S. market."
commented Dr. Albert Friesen, Chief
Executive Officer for Medicure. "We look forward to the growth of
our portfolio of cardiovascular products."
About Medicure Inc.
Medicure is a pharmaceutical
company focused on the development and commercialization of
therapies for the U.S. cardiovascular market. The present focus of
the Company is the marketing and distribution of
AGGRASTAT® (tirofiban hydrochloride) injection and
ZYPITAMAGTM (pitavastatin) tablets in the United States, where they are sold through
the Company's U.S. subsidiary, Medicure Pharma Inc. For more
information on Medicure please visit www.medicure.com. For
additional information about ZYPITAMAGTM, refer to the
full Prescribing Information.
About Reliance Life Sciences Private Limited
Reliance
Life Sciences Private Limited (RLS) is part of the Promoter Group
of Reliance Industries Limited. RLS is a research driven
organization developing business opportunities in bio-therapeutics
(plasma proteins, biosimilars and novel proteins), pharmaceuticals,
regenerative medicine, clinical research services, and molecular
medicine. The Reliance Group is India's largest private
sector enterprise, with annual revenues of $ 86 billion USD.
The Group's flagship company, Reliance Industries Limited
is India's largest private sector company and a Fortune
Global 100 company. RLS is a fully integrated life sciences
industry player with in-house capabilities in research,
pre-clinical and clinical development, process development, quality
management, commercial-scale manufacturing, and marketing. For
further information on Reliance Life Sciences please
visit http://www.rellife.com/
To be added to Medicure's e-mail list, please
visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this
press release that are not statements of historical fact,
including, without limitation, statements containing the words
"believes", "may", "plans", "will", "estimates", "continues",
"anticipates", "intends", "expects" and similar expressions, may
constitute "forward-looking information" within the meaning of
applicable Canadian and U.S. federal securities laws (such
forward-looking information and forward-looking statements are
hereinafter collectively referred to as "forward-looking
statements"). Forward-looking statements, include estimates,
analysis and opinions of management of the Company made in light of
its experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, the ability of
AGGRASTAT® to provide
benefits to COVID-19 patients, expected future growth
in revenues, stage of development, additional capital requirements,
risks associated with the completion and timing of clinical trials
and obtaining regulatory approval to market the Company's products,
the ability to protect its intellectual property, dependence upon
collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in
the industry. Such statements are based on a number of assumptions
which may prove to be incorrect, including, but not limited to,
assumptions about: general business and economic conditions; the
impact of changes in Canadian-US dollar and other foreign exchange
rates on the Company's revenues, costs and results; the timing of
the receipt of regulatory and governmental approvals for the
Company's research and development projects; the availability of
financing for the Company's commercial operations and/or research
and development projects, or the availability of financing on
reasonable terms; results of current and future clinical trials;
the uncertainties associated with the acceptance and demand for new
products and market competition. The foregoing list of important
factors and assumptions is not exhaustive. The Company undertakes
no obligation to update publicly or otherwise revise any
forward-looking statements or the foregoing list of factors, other
than as may be required by applicable legislation. Additional
discussion regarding the risks and uncertainties relating to the
Company and its business can be found in the Company's other
filings with the applicable Canadian securities regulatory
authorities or the US Securities and Exchange Commission, and in
the "Risk Factors" section of its Form 20F for the year ended
December 31, 2019.
View original
content:http://www.prnewswire.com/news-releases/medicure-announces-an-agreement-with-reliance-life-sciences-for-the-marketing-rights-of-a-cardiovascular-biosimilar-301145432.html
SOURCE Medicure Inc.